Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04446117
Title Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)
Acronym CONTACT-02
Recruitment Active, not recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Exelixis
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG


No variant requirements are available.